![Shao Lan Fu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shao Lan Fu
Voorzitter bij PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD
Vermogen: 351 M $ op 31-05-2024
Actieve functies van Shao Lan Fu
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD | Voorzitter | 11-12-2023 | - |
Harbin Pacific Biopharmaceutical Co., Ltd.
![]() Harbin Pacific Biopharmaceutical Co., Ltd. BiotechnologyHealth Technology Part of Pacific Shuanglin Bio-pharmacy Co., Ltd., Harbin Pacific Biopharmaceutical Co., Ltd. is a company based in Beijing, China. The Chinese company is known for its high plasma utilization rate, wide range of products, and rational product structure. The company's main products include human albumin, intravenous human immunoglobulin (pH4), lyophilized intravenous human immunoglobulin (pH4), intravenous hepatitis B human immunoglobulin (pH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies human immunoglobulin, human immunoglobulin, and human fibrinogen, with a total of nine varieties and twenty-nine specifications. Seven of their products have been recognized as national and provincial high-tech products. Shao Lan Fu has been the CEO of the company since 1992. Harbin Pacific Biopharmaceutical Co., Ltd. was acquired by Pacific Shuanglin Bio-pharmacy Co., Ltd. on January 21, 2021, for $973.36 million. | Algemeen Directeur | 01-05-1992 | - |
Voorzitter | 01-05-2009 | - |
Loopbaan van Shao Lan Fu
Eerdere bekende functies van Shao Lan Fu
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Everest Green Ltd.
![]() Everest Green Ltd. BiotechnologyHealth Technology Pacific Biopharmaceutical Ltd. was an investment holding company, which engaged in the research, development, manufacture, and sale of plama-derived biopharmaceutical products. It provided treatment for people suffering from genetic diseases, bleeding disorders, immunodeficiency, pulmonary disorders, neurological disorders, traumatic of hemorrhagic shocks, severe burns, liver cirrhosis, and infectious diseases. Its products included Albumin, Immunoglobulins, and Coagulation factors. The company was founded by Fu Shao Lan on March 20, 2015 and was headquartered in Harbin, China. | Algemeen Directeur | 20-03-2015 | - |
Voorzitter | 20-03-2015 | - | |
Oprichter | 20-03-2015 | - |
Opleiding van Shao Lan Fu
Chinese Academy of Sciences | Undergraduate Degree |
Cambridge Judge Business School | Graduate Degree |
Statistieken
Internationaal
China | 4 |
Kaaimaneilanden | 2 |
Verenigd Koninkrijk | 2 |
Operationeel
Chairman | 3 |
Chief Executive Officer | 2 |
Founder | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Everest Green Ltd.
![]() Everest Green Ltd. BiotechnologyHealth Technology Pacific Biopharmaceutical Ltd. was an investment holding company, which engaged in the research, development, manufacture, and sale of plama-derived biopharmaceutical products. It provided treatment for people suffering from genetic diseases, bleeding disorders, immunodeficiency, pulmonary disorders, neurological disorders, traumatic of hemorrhagic shocks, severe burns, liver cirrhosis, and infectious diseases. Its products included Albumin, Immunoglobulins, and Coagulation factors. The company was founded by Fu Shao Lan on March 20, 2015 and was headquartered in Harbin, China. | Health Technology |
Harbin Pacific Biopharmaceutical Co., Ltd.
![]() Harbin Pacific Biopharmaceutical Co., Ltd. BiotechnologyHealth Technology Part of Pacific Shuanglin Bio-pharmacy Co., Ltd., Harbin Pacific Biopharmaceutical Co., Ltd. is a company based in Beijing, China. The Chinese company is known for its high plasma utilization rate, wide range of products, and rational product structure. The company's main products include human albumin, intravenous human immunoglobulin (pH4), lyophilized intravenous human immunoglobulin (pH4), intravenous hepatitis B human immunoglobulin (pH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies human immunoglobulin, human immunoglobulin, and human fibrinogen, with a total of nine varieties and twenty-nine specifications. Seven of their products have been recognized as national and provincial high-tech products. Shao Lan Fu has been the CEO of the company since 1992. Harbin Pacific Biopharmaceutical Co., Ltd. was acquired by Pacific Shuanglin Bio-pharmacy Co., Ltd. on January 21, 2021, for $973.36 million. | Health Technology |
- Beurs
- Insiders
- Shao Lan Fu
- Ervaring